Selected article for: "BCG vaccination policy and death case"
Author: Jirjees, Feras J.; Dallal Bashi, Yahya H.; Al-Obaidi, Hala J.
Title: COVID-19 Death and BCG Vaccination Programs Worldwide
  • Cord-id: 7dxez7ww
  • Document date: 2020_9_4
    • ID: 7dxez7ww
    Snippet: Several clinical trials are being conducted worldwide to investigate the protective effect of the bacillus Calmette-Guérin (BCG) vaccine against death in healthcare providers who are working directly with coronavirus disease 2019 (COVID-19) patients. Clinical studies suggested that certain live vaccines, particularly the BCG vaccine, could reduce the mortality due to other diseases caused by non-targeted pathogens, most probably through the nonspecific effects (heterologous effects). By the end
    Document: Several clinical trials are being conducted worldwide to investigate the protective effect of the bacillus Calmette-Guérin (BCG) vaccine against death in healthcare providers who are working directly with coronavirus disease 2019 (COVID-19) patients. Clinical studies suggested that certain live vaccines, particularly the BCG vaccine, could reduce the mortality due to other diseases caused by non-targeted pathogens, most probably through the nonspecific effects (heterologous effects). By the end of May 2020, the available information on the COVID-19 pandemic indicated the great effect of the BCG vaccine in reducing the number of COVID-19 death cases. The occurrence of death due to COVID-19 was found to be 21-fold lower in countries with a national BCG vaccination policy than in countries without such a policy, based on the medians of COVID-19 death case per 1 million of the population in these two groups of countries (p<0.001, MannWhitney test). Therefore, it can be concluded that the early establishment of a BCG vaccination policy in any country is a key element in reducing the number of COVID-19 and tuberculosis death cases.

    Search related documents:
    Co phrase search for related documents
    • acute sars respiratory syndrome coronavirus and adaptive immune system activation: 1, 2
    • acute sars respiratory syndrome coronavirus and low influenza: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13
    • acute sars respiratory syndrome coronavirus and low reason: 1
    • acute sars respiratory syndrome coronavirus and low respiratory: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute sars respiratory syndrome coronavirus and low respiratory tract: 1, 2, 3, 4, 5, 6
    • acute sars respiratory syndrome coronavirus and lung damage: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute sars respiratory syndrome coronavirus and lymph node: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute sars respiratory syndrome coronavirus and macrophage inflammatory protein 1a: 1, 2
    • adaptive immune system and lung damage: 1, 2, 3
    • low influenza and lung damage: 1
    • low respiratory and lung damage: 1, 2, 3
    • lung damage and lymph node: 1, 2